TACE with Lenvatinib and Pembrolizumab in Unresectable, Nonmetastatic Hepatocellular Carcinoma: Results from the LEAP-012 Trial
Radiology: Imaging Cancer · 01.03.2026 · 8 (2)
DOI: 10.1148/rycan.269003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Radiology: Imaging Cancer, erschienen am 01.03.2026. Verfasst von Noreen S Siddiqi. Die Arbeit nennt 1 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
ORCID-Profile: Noreen S Siddiqi
Förderung
- NCI NIH HHS
Zitieren
APA
Siddiqi, N. S. (2026). TACE with Lenvatinib and Pembrolizumab in Unresectable, Nonmetastatic Hepatocellular Carcinoma: Results from the LEAP-012 Trial. Radiology: Imaging Cancer, 8(2). https://doi.org/10.1148/rycan.269003
Vancouver
Siddiqi NS. TACE with Lenvatinib and Pembrolizumab in Unresectable, Nonmetastatic Hepatocellular Carcinoma: Results from the LEAP-012 Trial. Radiology: Imaging Cancer. 2026;8(2). doi:10.1148/rycan.269003
BibTeX
@article{Siddiqi2026,
author = {Siddiqi, Noreen S},
title = {TACE with Lenvatinib and Pembrolizumab in Unresectable, Nonmetastatic Hepatocellular Carcinoma: Results from the LEAP-012 Trial},
journal = {Radiology: Imaging Cancer},
year = {2026},
volume = {8},
number = {2},
doi = {10.1148/rycan.269003}
}
EUVIMED